Home

Driving the Data-Rich Future of OSDs
Data-rich, data-led, data-driven — these terms increasingly define modern oral solid dose development. In this roundtable, industry leaders discuss what it will take to navigate this next phase of OSD innovation. read more
Peptide-to-Small-Molecule Translation
Recent advances are turning what was once a trial-and-error exercise into a disciplined and reproducible design workflow. read more
Particle Size Meets Chemistry
As material complexity and regulatory expectations grow, LD-PCRS correlative characterization will support robust formulation design, process control, and risk-based decision-making. read more
Handling Machinability Challenges with Hard Shell Capsules
Machinability issues linked to capsule-related factors can disrupt production, increase waste and jeopardize delivery timelines. read more

BMS Secures Priority Review for Heart Drug in Adolescents
June 08, 2026
In a phase 3 trial, the drug met its primary endpoint and showed a safety profile consistent with that observed in adults. read more
Lilly's Oral GLP-1 Gets Phase 3 Win, Teeing Up Type 2 Diabetes Filing
June 08, 2026
Lilly shared phase 3 data for its once-daily GLP-1 tablet, Foundayo, across a broader set of patient populations than its approved obesity indication. read more
FDA Hits Cingulate with CRL for ADHD Tablet, Citing CMC Issues
June 05, 2026
The letter did not raise any concerns regarding the clinical safety or efficacy of CTx-1301. read more